# Ketamine Use for ED Sedation: Pharmacologic Basis, Clinical Applications, and Safety Considerations

**Authors:** Sabrina Montoya, Christian Andrés Soto Cordero, Elia L Zamora, Ronald Chavarría, Diego Alvarez Ramirez

PMC · DOI: 10.7759/cureus.103774 · Cureus · 2026-02-17

## TL;DR

Ketamine is a valuable drug in emergency medicine for sedation due to its unique effects on the brain and body, offering effective pain relief and safety in various clinical situations.

## Contribution

This paper provides a comprehensive overview of ketamine's pharmacology, clinical uses, and safety in emergency department sedation.

## Key findings

- Ketamine's NMDA receptor antagonism provides analgesia and sedation while preserving airway reflexes.
- Ketamine is effective in pediatric patients and trauma cases due to its sympathomimetic activity and minimal adverse effects.
- Standardized dosing and coadministration with benzodiazepines enhance ketamine's safety and efficacy in the ED.

## Abstract

Ketamine is a versatile pharmacologic agent whose unique receptor interactions explain its broad applicability in emergency medicine. Its primary mechanism of action is non-competitive antagonism of N-methyl-D-aspartate (NMDA) receptors, which underlies its dissociative, anesthetic, and analgesic properties. By reducing excitatory neurotransmission and limiting glutamatergic activity, ketamine provides effective sedation while helping prevent neurotoxicity. Additional interactions with opioid, monoaminergic, and cholinergic systems contribute to its analgesic and psychotropic effects, reinforcing its neuroprotective and antidepressant potential. Ketamine is rapidly absorbed, crosses the blood-brain barrier efficiently, and is metabolized in the liver by cytochrome P450 enzymes CYP3A4 and CYP2B6 into active metabolites such as hydroxynorketamine. Its short half-life and multiple routes of administration, including IV, intramuscular (IM), and intranasal, allow for flexible use in different clinical contexts. In the ED, ketamine is used for procedural sedation, fracture and dislocation reduction, wound repair, and trauma management. Its dissociative properties ensure adequate analgesia and amnesia while preserving airway reflexes, reducing the need for additional anesthetic agents. It is particularly valuable in pediatric patients, providing effective sedation and pain control with minimal adverse effects. In cases of trauma, burns, or shock, the sympathomimetic activity of ketamine helps maintain cardiovascular tone and perfusion, offering an advantage over opioids, which may cause hypotension or respiratory depression. Adverse reactions are uncommon but may include laryngospasm, hypertension, tachycardia, or psychological emergence phenomena such as agitation or hallucinations. Coadministration of benzodiazepines can mitigate these effects and improve patient comfort during recovery. Standardized dosing protocols, typically 0.15-0.30 mg/kg IV for analgesia and 2-5 mg/kg IM for sedation, ensure both efficacy and safety. Comparative studies indicate that ketamine maintains hemodynamic stability better than etomidate and has a more favorable respiratory profile compared with benzodiazepine-opioid combinations. Overall, ketamine remains a cornerstone agent for emergency procedural sedation due to its rapid onset, reliability, and adaptability across a wide range of patient populations.

## Linked entities

- **Chemicals:** ketamine (PubChem CID 3821), hydroxynorketamine (PubChem CID 133669)

## Full-text entities

- **Genes:** CYP2B6 (cytochrome P450 family 2 subfamily B member 6) [NCBI Gene 1555] {aka CPB6, CYP2B, CYP2B7, CYPIIB6, EFVM, IIB1}
- **Diseases:** neurotoxicity (MESH:D020258), hypertension (MESH:D006973), pain (MESH:D010146), burns (MESH:D002056), fracture (MESH:D050723), laryngospasm (MESH:D007826), tachycardia (MESH:D013610), respiratory depression (MESH:D012131), amnesia (MESH:D000647), trauma (MESH:D014947), hallucinations (MESH:D006212), dislocation (MESH:D004204), shock (MESH:D012769), analgesia (MESH:D000699), hypotension (MESH:D007022), agitation (MESH:D011595)
- **Chemicals:** etomidate (MESH:D005045), benzodiazepine (MESH:D001569), hydroxynorketamine (-), Ketamine (MESH:D007649)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13001689/full.md

## References

28 references — full list in the complete paper: https://tomesphere.com/paper/PMC13001689/full.md

---
Source: https://tomesphere.com/paper/PMC13001689